Drug Profile


Latest Information Update: 21 Jan 2008

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Developer AstraZeneca; Pharmacia Corporation
  • Class Anti-inflammatories; Benzoic acids
  • Mechanism of Action Immunomodulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Rheumatic disorders

Most Recent Events

  • 17 Jan 2002 No-Development-Reported for Inflammatory bowel disease in Sweden (Unknown route)
  • 17 Jan 2002 No-Development-Reported for Rheumatic disorders in Sweden (Unknown route)
  • 31 Oct 1998 Phase-I clinical trials for Rheumatic disorders in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top